Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
Corbus Pharmaceuticals reported updated Phase 1/2 data for CRB-701, showing a 42.9% confirmed objective response rate in second-line oropharyngeal squamous cell carcinoma (OPSCC) and 34.4% in cervical cancer at the 3.6 mg/kg dose. The drug demonstrated a manageable safety profile with only 2.8% treatment discontinuations and no Grade 5 events, supporting its potential in HPV-driven tumors with high Nectin-4 expression.
Key figures
- Drug Name
- CRB-701 (SYS6002)
- Phase Of Trial
- Phase 1/2
- Tempo 1 n
- 250
- Opsc dor 3.6mg
- 6.3 months
- Opsc pfs 3.6mg
- 5.6 months
- Grade 3 ae rate
- 19.2%
- Grade 4 ae rate
- 0.9%
- Opsc corr 3.6mg
- 42.9%
- Safety population
- 317
- Cervical dor 3.6mg
- 8.0 months
- Cervical pfs 3.6mg
- 4.3 months
- Cervical corr 3.6mg
- 34.4%
- Discontinuation rate
- 2.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.